Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 6/20 | 0.40 |
| ▸ | HTR2A | P28223 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3919544 | 1.00 | AOC3 (0.46) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL2561336 | 0.86 | POLB (0.45) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL7839156 | 0.86 | AOC3 (0.40) | AOC3LMNAHRH1HTR2ATAAR1 | |
| SCHEMBL8443421 | 0.85 | HRH1 (0.46) | HRH1HTR2ATAAR1 | |
| SCHEMBL15105467 | 0.85 | SIGMAR1 (0.44) | AOC3LMNAHRH1HTR2ASIGMAR1 | |
| SCHEMBL11103930 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL11103470 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL11782470 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL329081 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 | |
| SCHEMBL15105361 | 0.83 | HTR2A (0.45) | HTR2ASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288569-B2 | Carbonyl asymmetric alkylation | SANDOZ AG (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8288569-B2 | Carbonyl asymmetric alkylation | SANDOZ AG (CH) | 2012-10-16 | — | — | US | disclosed |
| EP-1966127-B1 | CARBONYL ASYMMETRIC ALKYLATION | SANDOZ AG (CH) | 2011-04-06 | — | — | EP | disclosed |
| US-20110009648-A1 | Carbonyl Asymmetric Alkylation | SANDOZ AG (CH) | 2011-01-13 | — | — | US | disclosed |
| US-20110009648-A1 | Carbonyl Asymmetric Alkylation | SANDOZ AG (CH) | 2011-01-13 | — | — | US | disclosed |
| EP-1966127-A1 | CARBONYL ASYMMETRIC ALKYLATION | Sandoz AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007082771-A1 | CARBONYL ASYMMETRIC ALKYLATION | SANDOZ AG (CH) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007082771-A1 | CARBONYL ASYMMETRIC ALKYLATION | SANDOZ AG (CH) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009648-A1 | Carbonyl Asymmetric Alkylation | COASY, ADH5, SI | AOC3 345/4885LMNA 1282/4885HRH1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.